Hospitals & Doctors
Premium Hospitals Selected · Senior Experts Gathered, For Your Reassuring Health Journey
Prof. Li Jin
Languages:
A leading figure in clinical research of innovative cancer drugs in China, former chairman of CSCO, and chairman of the Asian Cancer League
Prof. Li Jin is a world-renowned specialist in gastrointestinal oncology and a leading figure in innovative anti-cancer drug clinical research in China. With nearly 40 years of clinical and research experience, he conducted postdoctoral research in tumor gene and biotherapy at Yale University under the mentorship of U.S. National Academy of Sciences member Prof. Alan Garen. He has published over 150 papers as first or corresponding author in top international journals including JAMA, JCO, Lancet Oncology, and PNAS. In 2014, he led the world’s first Phase I-III clinical trial of apatinib for gastric cancer and delivered the first keynote speech by a Chinese oncologist at the ASCO Annual Meeting. In 2017, his landmark FRESCO trial, published in JAMA, led to the approval of fruquintinib, China’s first domestically developed targeted therapy for metastatic colorectal cancer. As principal investigator, he has led over 200 new drug clinical trials, helping bring more than 10 anti-cancer drugs to market globally. He has received the National Science and Technology Progress Award (Second Class) and the title of National Famous Doctor.
20+ Yrs Practice
16 SCI Papers
UCSF Postdoc
China’s 1st International CAR-T Leads
Focus on Disease Treatment & Therapeutic Methods
We focus on specific sub-segments of major/recurrent diseases,
providing treatment options with high benefits and fewer complications.
| Disease | Treatment | Advantages |
|---|---|---|
| Gastric Cancer | Targeted therapy, immunotherapy, MDT approach | Led the global Phase I-III trial of apatinib, pioneering targeted therapy for gastric cancer |
| Colorectal Cancer | Third-line targeted therapy, immunotherapy combinations | FRESCO trial led to fruquintinib approval, published in JAMA |
| Esophageal Cancer | Neoadjuvant immunotherapy, targeted + chemotherapy | Leading multiple international multi-center clinical trials |
| Pancreatic & Other GI Cancers | Personalized precision therapy, cell therapy combinations | Cutting-edge innovative treatments at Gobroad Research Hospital |
Target Patient Populations
- Patients with advanced gastrointestinal malignancies (gastric, colorectal, esophageal, pancreatic cancers)
- patients seeking innovative treatment options after prior therapy failure
- candidates for cutting-edge clinical trials
- patients requiring multidisciplinary comprehensive management of complex tumors.
Career Path
Strictly Aligned With The Promotion Chain For Medical Experts, Supporting In-Depth Tracing Of Domestic And International Education And Verification Of Honors.
Career Milestones
Obtained Master’s and PhD; Director of Medical Oncology, Fudan University Shanghai Cancer Center
Lifetime Professor at Tongji University; Chief Scientist & President, Shanghai Gobroad Cancer Hospital
Professional Memberships
Shanghai Pubin Children’s Hospital
National Children’s Medical Center / Shanghai Children’s Medical Center
SJTU School of Medicine
Shanghai Medical Association Pediatrics Branch
Shanghai Medical Association Allergy Branch
Chinese Medical Association Pediatrics Respiratory Group
Chinese Medical Association Allergy Branch
Clinical Highlights
CAR-T Therapy Experience
Successfully completed CAR-T cell therapy for China’s first cohort of international patients (including UK, New Zealand, Singapore, etc.)
International Patient Scope
Treated overseas patients from 5+ countries, with 100% successful discharge rates and fantastic follow-up profiles
MDT Team Leadership
Multidisciplinary Team: Led the establishment of SinoAmerican Health’s CAR-T Therapy Center MDT team, with full support from Cardiology, ICU, Pulmonology, and other specialties
Academic Achievements
Multi-Center Research And Academic Accumulation Across Domestic And International Locations
~40
Years of Practice
150+
Publications
50+
Graduate Students Mentored
10+
Drugs Brought to Market
Professional Memberships
- UCSF Multiple Myeloma Translational Medicine Fund
- National Natural Science Foundation of China （NSFC）
- Shanghai Pujiang Talent Program
- Chinese Medical Doctor Association Multiple Myeloma Special Fund
Representative Publications
FRESCO Trial: Phase III study of fruquintinib in mCRC, published in JAMA (2018)
2005-04-20
2023 (First Author)
Phase I-III study of apatinib in advanced gastric cancer, first keynote at ASCO (2014)
2005-04-20
2023 (Co-author)
SHR-A1811 Phase III for HER2+ CRC, presented at ASCO 2026
2005-04-20
(Corresponding Author, jointly with Dr. Vicky H. Lee)
CLDN18.2 ADC + PD-1 first-line for advanced gastric cancer Phase I/II, ASCO 2026 poster
2005-04-20
(Corresponding Author, jointly with Dr. Vicky H. Lee)
Extensive publications in JCO, Lancet Oncology, PNAS and other prestigious journals
2005-04-20
(Corresponding Author, jointly with Dr. Vicky H. Lee)
Academic Exchanges
- Invited keynote speaker at ASCO Annual Meetings in 2014, 2016, and 2026
- Chair of Federation of Asian Cancer Organizations (FACO)
- Established China's first research-oriented hospital clinical research platform
- Co-building Clinical Drug Research Institute with China Pharmaceutical University
Get Your Free No-obligation Medical
Consultation Now